Long-term outcomes following stereotactic body radiotherapy boost for oropharyngeal squamous cell carcinoma

References

• Al-Mamgani A, Van Rooij P, Sewnaik A, et al. Brachytherapy or stereotactic body radiotherapy boost for early-stage oropharyngeal cancer: comparable outcomes of two different approaches. Oral Oncol. 2013;49:1018–1024.
   PubMed Web of Science ®Google Scholar
• Teguh DN, Levendag PC, Noever I, et al. Treatment techniques and site considerations regarding dysphagia-related quality of life in cancer of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys. 2008;72:1119–1127.
   PubMed Web of Science ®Google Scholar
• Baliga S, Kabarriti R, Ohri N, et al. Stereotactic body radiotherapy for recurrent head and neck cancer: a critical review. Head Neck. 2017;39:595–601.
   PubMed Web of Science ®Google Scholar
• Maciejewski B, Withers HR, Taylor JM, et al. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx. Part 2. Normal tissue responses: acute and late effects. Int J Radiat Oncol Biol Phys. 1990;18:101–111.
   PubMed Web of Science ®Google Scholar
• Fletcher GH. Hypofractionation: lessons from complications. Radiother Oncol. 1991;20:10–15.
   PubMed Web of Science ®Google Scholar
• Lee DS, Kim YS, Cheon JS, et al. Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment. Radiat Oncol. 2012;7:85.
   PubMed Web of Science ®Google Scholar
• Cengiz M, Özyiğit G, Yazici G, et al. Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2011;81:104–109.
   PubMed Web of Science ®Google Scholar
• Kodani N, Yamazaki H, Tsubokura T, et al. Stereotactic body radiation therapy for head and neck tumor: disease control and morbidity outcomes. J Radiat Res. 2011;52:24–31.
   PubMed Web of Science ®Google Scholar
• Siddiqui F, Patel M, Khan M, et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region . Int J Radiat Oncol Biol Phys. 2009;74:1047–1053.
   PubMed Web of Science ®Google Scholar
• Karam I, Yao M, Heron DE, et al. Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers. Future Oncol. 2017;13:603–613.
   PubMed Web of Science ®Google Scholar
• Rwigema JC, Heron DE, Ferris RL, et al. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol. 2011;34:372–379.
   PubMed Web of Science ®Google Scholar
• Vargo JA, Ferris RL, Ohr J, et al. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2015;91:480–488.
   PubMed Web of Science ®Google Scholar
• Liu F, Xiao JP, Xu GZ, et al. Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma. Radiat Oncol. 2013;8:157.
   PubMed Web of Science ®Google Scholar
• Hara W, Loo BW, Jr, Goffinet DR, et al. Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2008;71:393–400.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Ogita M, Himei K, et al. Hypofractionated stereotactic radiotherapy using CyberKnife as a boost treatment for head and neck cancer, a multi-institutional survey: impact of planning target volume. Anticancer Res 2014;34:5755–5759.
   PubMed Web of Science ®Google Scholar
• Owen D, Iqbal F, Pollock BE, et al. Long-term follow-up of stereotactic radiosurgery for head and neck malignancies. Head Neck. 2015;37:1557–1562.
   PubMed Web of Science ®Google Scholar
• Al-Mamgani A, van Rooij P, Tans L, et al. A prospective evaluation of patient-reported quality-of-life after (chemo)radiation for oropharyngeal cancer: which patients are at risk of significant quality-of-life deterioration?. Radiother Oncol. 2013;106:359–363.
   PubMed Web of Science ®Google Scholar
• Baker S, Verduijn G, Petit S, et al. Locoregional failures and their relation to radiation fields following stereotactic body radiotherapy boost for oropharyngeal squamous cell carcinoma. Head Neck. 2019. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Fowler JF. Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer? (Int j radiat oncol biol phys 2007;68:1491-1495). Int J. Int J Radiat Oncol Biol Phys. 2008;71:326–329.
   PubMed Web of Science ®Google Scholar
• Dronkers EAC, Koljenovic S, Verduijn GM, et al. Nodal response after 46 Gy of intensity-modulated radiotherapy is associated with human papillomavirus-related oropharyngeal carcinoma. Laryngoscope. 2018;128:2333–2340.
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Hofstede TM, Sturgis EM, et al. ORN and radiation dose to the mandible in patients with oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2013;85:415–420.
   PubMed Web of Science ®Google Scholar
• Ward MC, Ross RB, Koyfman SA, et al. Modern image-guided intensity-modulated radiotherapy for oropharynx cancer and severe late toxic effects: implications for clinical trial design. JAMA Otolaryngol Head Neck Surg. 2016;142:1164–1170.
   PubMed Web of Science ®Google Scholar
• Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014;32:3858–3866.
   PubMed Web of Science ®Google Scholar
• Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 2010;76:1333–1338.
   PubMed Web of Science ®Google Scholar
• de Almeida JR, Byrd JK, Wu R, et al. A systematic review of transoral robotic surgery and radiotherapy for early oropharynx cancer: a systematic review. Laryngoscope. 2014;124:2096–2102.
   PubMed Web of Science ®Google Scholar
• Garden AS, Asper JA, Morrison WH, et al. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer. 2004;100:1171–1178.
   PubMed Web of Science ®Google Scholar
• Melchers LJ, Mastik MF, Samaniego Cameron B, et al. Detection of HPV-associated oropharyngeal tumours in a 16-year cohort: more than meets the eye. Br J Cancer. 2015;112:1349–1357.
   PubMed Web of Science ®Google Scholar
• Henneman R, Van Monsjou HS, Verhagen CV, et al. Changes of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma and Effects on Survival in the Netherlands Cancer Institute, 1980-2009. Anticancer Res. 2015;35:4015–4022.
   PubMed Web of Science ®Google Scholar
• Thomas K, Martin T, Gao A, et al. Interruptions of Head and Neck Radiotherapy Across Insured and Indigent Patient Populations. J Pancreas. 2017;13:e319–e328.
   PubMed Web of Science ®Google Scholar
• Russo G, Haddad R, Posner M, et al. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008;13:886–898.
   PubMed Web of Science ®Google Scholar
• Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.
   PubMed Web of Science ®Google Scholar
• Selek U, Garden AS, Morrison WH, et al. Radiation therapy for early-stage carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys. 2004;59:743–751.
   PubMed Web of Science ®Google Scholar
• Nabil S, Samman N. Risk factors for osteoradionecrosis after head and neck radiation: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:54–69.
   PubMed Web of Science ®Google Scholar
• Setton J, Lee NY, Riaz N, et al. A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. Cancer. 2015;121:294–301.
   PubMed Web of Science ®Google Scholar
• Silverstein P. Smoking and wound healing. Am J Med. 1992;93(1A):22S–24S.
   PubMed Web of Science ®Google Scholar
• Chen AM, Chen LM, Vaughan A, et al. Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. Int J Radiat Oncol Biol Phys. 2011;79:414–419.
   PubMed Web of Science ®Google Scholar
• Koga DH, Salvajoli JV, Alves FA. Dental extractions and radiotherapy in head and neck oncology: review of the literature. Oral Dis. 2008;14:40–44.
   PubMed Web of Science ®Google Scholar